Table 1.
Demographics and clinical characteristics of the sample (N = 317).
| Characteristic | Category | Mean ± SD (range) or n (%) |
|---|---|---|
| Age (years) | 52.78 ± 10.41 (26–82) | |
| 20–29 | 3 (0.95) | |
| 30–39 | 31 (9.78) | |
| 40–49 | 93 (29.34) | |
| 50–59 | 107 (33.75) | |
| ≥60 | 83 (26.18) | |
| Stage of tumor | I | 6 (1.96) |
| II | 224 (73.20) | |
| III | 76 (24.84) | |
| Initial clinical T stage | 1 | 30 (9.86) |
| 2 | 212 (69.74) | |
| 3 | 32 (10.53) | |
| 4 | 29 (9.54) | |
| Initial clinical N stage | 0 | 114 (37.50) |
| 1 | 148 (48.68) | |
| 2 | 19 (6.25) | |
| 3 | 23 (7.57) | |
| Ki-67 | Low (<14%) | 34 (11.26) |
| High (≥14%) | 268 (88.75) | |
| Tumor subtype | HR+/HER2− | 108 (34.07) |
| HR+/HER2+ | 49 (15.46) | |
| HR−/HER2+ | 58 (18.30) | |
| TNBC | 102 (32.18) | |
| Chemotherapy regimen | AC-T regimen | 214 (67.51) |
| TCHP regimen | 84 (26.50) | |
| Other | 19 (5.99) | |
| Duration of neoadjuvant chemotherapy | (days) | 142 ± 30.86 (49–196) |
| BMI at baseline | <18.5 (underweight) | 9 (2.84) |
| 18.5–22.9 (normal) | 132 (41.64) | |
| 23–24.9 (overweight) | 82 (25.87) | |
| ≥25 (obese) | 94 (29.65) |
AC-T regimen, combination of an anthracycline and cyclophosphamide, followed by a taxane; BMI, body mass index; HER2−, human epidermal growth factor receptor 2-negative; HER2+, human epidermal growth factor receptor 2-positive; HR−, hormone receptor-negative; HR+, hormone receptor-positive; TCHP regimen, docetaxel, carboplatin, trastuzumab, and pertuzumab; TNBC, triple negative breast cancer.